BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

REVISED 10/02/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

Version 2007.9

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS *Effective 4/2/07*	LOTREL (benazepril/amlodipine) TARKA (trandolapril/verapamil)	amlodipine/benazepril LEXXEL (enalapril/felodipine)	Each of the preferred agents must be tried for at least two weeks each before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients starting therapy in this class must show a documented allergy to the preferred agents before a non-preferred agent will be authorized.
ACNE AGENTS, TOPICAL *Effective 4/2/07*	**ANTIBIOTICS**		A trial of 30 days of one of the preferred agents in each category will be required before a non-preferred agent will be authorized. (In cases of pregnancy, a trial of retinoids will not be required.) PA required after 17 years of age for tretinoin products.
	AKNE-MYCIN (erythromycin) clindamycin erythromycin	CLINDAGEL (clindamycin) CLINDAREACH (clindamycin)[NR] EVOCLIN (clindamycin)	
	RETINOIDS		
	RETIN-A MICRO (tretinoin)[CL] TAZORAC (tazarotene) tretinoin[CL]	DIFFERIN (adapalene)	
	OTHERS		
	AZELEX (azelaic acid) BENZACLIN (benzoyl peroxide/clindamycin) benzoyl peroxide CLINAC BPO (benzoyl peroxide) DUAC (benzoyl peroxide/ clindamycin) sodium sulfacetamide	BENZAMYCIN PAK (benzoyl peroxide/erythromycin) BENZIQ (benzoyl peroxide) BREVOXYL (benzoyl peroxide) erythromycin/benzoyl peroxide INOVA (benzoyl peroxide) INOVA 4/1 (benzoyl peroxide/ salicylic acid) KLARON (sodium sulfacetamide) LAVOCLEN (benzoyl peroxide)[NR] NEOBENZ MICRO (benzoyl peroxide) NUOX (benzoyl peroxide/sulfur) SULFOXYL (benzoyl peroxide/sulfur) TRIAZ (benzoyl peroxide) ZACLIR (benzoyl peroxide) ZIANA (clindaymcyin/tretinoin)[NR] ZODERM (benzoyl peroxide)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
[CL] - Requires Clinical PA
[NR] – New drug has not been reviewed by P & T Committee

BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

REVISED 10/02/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

Version 2007.9

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ALZHEIMER'S AGENTS *Effective 10/01/07*	**CHOLINESTERASE INHIBITORS**		A trial of a preferred agent will be required before a non-preferred agent In this class will be authorized. Currrent prescriptions for Razadyne and Razadyne ER will be grandfathered.
	ARICEPT (donepezil) ARICEPT ODT(donepezil) EXELON (rivastigmine)	COGNEX (tacrine) RAZADYNE (galantamine) RAZADYNE ER (galantamine)	
	NMDA RECEPTOR ANTAGONIST		
	NAMENDA (memantine)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
CL - Requires Clinical PA
NR – New drug has not been reviewed by P & T Committee

BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

REVISED 10/02/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

Version 2007.9

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANALGESICS, NARCOTIC - SHORT ACTING (Non-parenteral) *Effective 4/2/07*	APAP/codeine ASA/codeine codeine dihydrocodeine/ APAP/caffeine hydrocodone/APAP hydrocodone/ibuprofen hydromorphone levorphanol morphine oxycodone oxycodone/APAP oxycodone/ASA pentazocine/APAP pentazocine/naloxone propoxyphene/APAP tramadol tramadol/APAP	ACTIQ (fentanyl) butalbital/APAP/caffeine/codeine butalbital/ASA/caffeine/codeine COMBUNOX (oxycodone/ibuprofen) DARVOCET (propoxyphene/APAP) DARVON (propoxyphene) DEMEROL (meperidine) DILAUDID (hydromorphone) fentanyl FENTORA (fentanyl)[NR] FIORICET W/ CODEINE (butalbital/APAP/caffeine/codeine) FIORINAL W/ CODEINE (butalbital/ASA/caffeine/codeine) LORCET, LORTAB (hydrocodone/APAP) LYNOX (oxycodone/APAP)[NR] meperidine OPANA (oxymorphone) OXYFAST, OXYIR (oxycodone) PANLOR (dihydrocodeine/ APAP/caffeine) PERCOCET (oxycodone/APAP) PERCODAN (oxycodone/ASA) propoxyphene TALACEN (pentazocine/APAP) TALWIN NX (pentazocine/naloxone) TYLENOL W/CODEINE (APAP/codeine) ULTRACET (tramadol/APAP) ULTRAM (tramadol) VICODIN (hydrocodone/APAP) VICOPROFEN (hydrocodone/ibuprofen)	Three of the preferred agents must be tried for at least 72 hours before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Fentanyl lozenges will only be approved as an adjunct to a long-acting agent. Fentanyl lozenges will not be approved for monotherapy. Limits: Quantities exceeding 240 tablets per 30 days (8 tablets/day) for agents containing 500 mg of acetaminophen will require a prior authorization and review by the Medical Director.

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANALGESICS, NARCOTIC - LONG ACTING (Non-parenteral)	DURAGESIC (fentanyl) KADIAN (morphine) methadone morphine ER	AVINZA (morphine) fentanyl MS CONTIN (morphine) OPANA ER (oxymorphone) ORAMORPH SR (morphine) oxycodone ER OXYCONTIN (oxycodone) ULTRAM ER (tramadol)	Three preferred narcotic analgesics, including at least one long-acting agent, must be tried for at least 72 hours before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Exception: Oxycodone ER will be authorized if a diagnosis of cancer is submitted without a trial of the preferred agents.
ANDROGENIC AGENTS *Effective 10/01/07*	ANDRODERM (testosterone) ANDROGEL (testosterone)	TESTIM (testosterone)	The non-preferred agents will be approved only if one of the exceptions on the PA form is present.
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs) *Effective 4/2/07*	**ANGIOTENSIN RECEPTOR BLOCKERS**		Each of the preferred agents in the corresponding group must be tried for at least two weeks each before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present.
	AVAPRO (irbesartan) BENICAR (olmesartan) COZAAR (losartan) DIOVAN (valsartan) MICARDIS (telmisartan)	ATACAND (candesartan) TEVETEN (eprosartan)	
	ARB COMBINATIONS		
	AVALIDE (irbesartan/HCTZ) BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT (valsartan/HCTZ) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ)	ATACAND-HCT (candesartan/HCTZ) EXFORGE (valsartan/amlodipine)[NR] TEVETEN-HCT (eprosartan/HCTZ)	

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANGIOTENSIN MODULATORS *Effective 10/01/07*	**ACE INHIBITORS**		Four of the preferred agents must be tried for at least 30 days each before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. A thirty-day trial of one of the preferred ACE or ARB agents, at the maximum tolerable dose, is required before Tekturna will be approved.
	ALTACE (ramipril) benazepril captopril enalapril fosinopril lisinopril quinapril	ACEON (perindopril) ACCUPRIL (quinapril) CAPOTEN (captopril) LOTENSIN (benazepril) MAVIK (trandolapril) moexepril MONOPRIL (fosinopril) PRINIVIL (lisinopril) trandolapril UNIVASC (moexepril) VASOTEC (enalapril) ZESTRIL (lisinopril)	
	ACE INHIBITOR/DIURETIC COMBINATIONS		
	benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ quinapril/HCTZ	ACCURETIC (quinapril/HCTZ) CAPOZIDE (captopril/HCTZ) LOTENSIN HCT (benazepril/HCTZ) moexepril/HCTZ MONOPRIL HCT (fosinopril/HCTZ) PRINZIDE (lisinopril/HCTZ) UNIRETIC (moexepril/HCTZ) VASERETIC (enalapril/HCTZ) ZESTORETIC (lisinopril/HCTZ)	
	DIRECT RENIN INHIBITORS		
		TEKTURNA (aliskerin)	
ANTICOAGULANTS, INJECTABLE[CL] *Effective 4/2/07*	ARIXTRA (fondaparinux) FRAGMIN (dalteparin) LOVENOX (enoxaparin)	INNOHEP (tinzaparin)	A trial of each of the preferred agents will be required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
[CL] - Requires Clinical PA
[NR] – New drug has not been reviewed by P & T Committee

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTICONVULSANTS *Effective 4/2/07*	**BARBITURATES**		Treatment naive patients must have a trial of a preferred agent before a non-preferred agent in its corresponding class will be authorized. Patients stabilized on non-preferred agents will receive authorization to continue these drugs. Additions to that therapy will require a trial of preferred agent in its respective class unless one of the exceptions on the PA form is present. The following step therapy edits will be applied to Lyrica. Lyrica will automatically be approved if there is a history of gabapentin utilization for 60 days, with a gap in therapy of no greater than 30 days. Overrides for Lyrica will not be given unless the dosage of gabapentin has been maximized to 1800 mg/ 24 hour for a diagnosis of chronic or neuropathic pain.
	mephobarbital phenobarbital primidone	MEBARAL (mephobarbital) MYSOLINE (primidone)	
	HYDANTOINS		
	PEGANONE (ethotoin) phenytoin	DILANTIN (phenytoin) EPITOL (phenytoin) PHENYTEK (phenytoin)	
	SUCCINIMIDES		
	CELONTIN (methsuximide) ethosuximide	ZARONTIN (ethosuximide)	
	BENZODIAZEPINES		
	clonazepam DIASTAT (diazepam rectal) diazepam	KLONOPIN (clonazepam)	
	ADJUVANTS		
	carbamazepine CARBATROL (carbamazepine) DEPAKOTE (divalproex) DEPAKOTE ER (divalproex) DEPAKOTE SPRINKLE (divalproex) dilvalproex EQUETRO (carbamazepine) FELBATOL (felbamate) gabapentin GABITRIL (tiagabine) KEPPRA (levetiracetam) LAMICTAL (lamotrigine) LYRICA (pregabalin)[CL] TOPAMAX (topiramate)	DEPAKENE (valproic acid) NEURONTIN (gabapentin) TEGRETOL (carbamazepine) TEGRETOL XR (carbamazepine) ZONEGRAN (zonisamide)	

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	TRILEPTAL (oxcarbazepine) valproic acid zonisamide		
ANTIDEPRESSANTS, OTHER (second generation, non-SSRI) *Effective 4/2/07*	bupropion SR CYMBALTA (duloxetine) EFFEXOR XR (venlafaxine) mirtazapine trazodone	bupropion IR bupropion XL DESYREL (trazodone) EFFEXOR (venlafaxine) EMSAM (selegiline) nefazodone REMERON (mirtazapine) venlafaxine WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion)	A non-preferred agent will only be authorized if there has been a six-week trial of an SSRI and a preferred agent in this class unless one of the exceptions on the PA form is present. Patients on a non-preferred agent will be authorized to continue on that agent.
ANTIDEPRESSANTS, SSRIs *Effective 10/01/07*	citalopram fluoxetine fluvoxamine paroxetine sertraline	CELEXA (citalopram) LEXAPRO (escitalopram) PAXIL (paroxetine) PAXIL CR (paroxetine) PEXEVA (paroxetine) PROZAC (fluoxetine) RAPIFLUX (fluoxetine) SARAFEM (fluoxetine) ZOLOFT (sertraline)	A trial of two of the preferred agents will be required, for at least 30 days, before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Patients currently on a non-preferred agent will be authorized to continue on that agent. Upon hospital discharge, patients admitted with a primary mental health diagnosis and have been stabilized on a non-preferred SSRI will receive authorization to continue that drug.
ANTIEMETICS, ORAL *Effective 10/01/07*	**CANNABINOIDS**		Cesamet will be authorized only for the treatment of nausea and vomiting associated with cancer chemotherapy for patients who have failed to respond adequately to conventional treatments such as promethazine or ondansetron and are over 18 years of age. Marinol will be authorized only for the treatment of anorexia associated with weight loss in patients with AIDS or cancer and unresponsive to megestrol, the prophylaxis of chemotherapy-induced nausea and vomiting unresponsive to ondansetron or promethazine and for patients between the ages of 18 and 65 years of age.
		CESAMET (nabilone) **MARINOL (dronabinol)**	
	5HT3 RECEPTOR BLOCKERS		A trial of Zofran is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ZOFRAN (ondansetron)	ANZEMET (dolasetron)	

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	ZOFRAN ODT (ondansetron)	KYTRIL (granisetron) ondansetron ondansetron ODT	Quantity limits for Zofran - 14 tablets per 21 days; in cases of hyperemesis during pregnancy, increased quantities may be authorized.
	SUBSTANCE P ANTAGONISTS		Quantity limits for Emend - 12 tablets per 28 days.
	EMEND (aprepitant)		
ANTIFUNGALS, ORAL [CL] *Effective 10/01/07*	clotrimazole fluconazole ketoconazole MYCOSTATIN Pastilles (nystatin) nystatin terbinafine	ANCOBON (flucytosine) DIFLUCAN (fluconazole) GRIFULVIN V (griseofulvin) griseofulvin GRIS-PEG (griseofulvin) itraconazole LAMISIL (terbinafine) MYCELEX (clotrimazole) MYCOSTATIN Tablets (nystatin) NIZORAL (ketoconazole) NOXAFIL (posaconazole) SPORANOX (itraconazole) VFEND (voriconazole)	Non-preferred agents will be approved only if one of the exceptions on the PA form is present. PA is required when limits are exceeded. PA is not required for Grifulvin-V Suspension for children up to 6 years of age for the treatment of tinea capitis.
ANTIFUNGALS, TOPICAL *Effective 10/01/07*	**ANTIFUNGALS**		Two of the preferred agents must be tried for at least two weeks each before one of the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
	econazole ketoconazole MENTAX (butenafine) NAFTIN (naftifine) nystatin	ciclopirox ERTACZO (sertaconazole) EXELDERM (sulconazole) LOPROX (ciclopirox) MYCOSTATIN (nystatin) NIZORAL (ketoconazole) OXISTAT (oxiconazole) PENLAC (ciclopirox) SPECTAZOLE (econazole) VUSION (miconazole/petrolatum/zinc oxide) XOLEGEL (ketoconazole)	
	ANTIFUNGAL/STEROID COMBINATIONS		
	clotrimazole/betamethasone nystatin/triamcinolone	LOTRISONE (clotrimazole/betamethasone) MYCOLOG (nystatin/triamcinolone)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
[CL] - Requires Clinical PA
[NR] – New drug has not been reviewed by P & T Committee

BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

REVISED 10/02/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

Version 2007.9

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTIHISTAMINES, MINIMALLY SEDATING *Effective 4/2/07*	**ANTIHISTAMINES**		A preferred agent, in the age appropriate dosage form, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ALAVERT (loratadine) CLARINEX Syrup (desloratadine) loratadine TAVIST-ND (loratadine)	ALLEGRA (fexofenadine) CLARINEX Tablets (desloratadine) CLARITIN (loratadine) fexofenadine ZYRTEC (cetirizine)	
	ANTIHISTAMINE/DECONGESTANT COMBINATIONS		
	ALAVERT-D (loratadine/pseudoephedrine) loratadine/pseudoephedrine SEMPREX-D (acrivastine/ pseudoephedrine)	ALLEGRA-D (fexofenadine/pseudoephedrine) CLARINEX-D (desloratadine/pseudoephedrine) CLARITIN-D (loratadine/pseudoephedrine) ZYRTEC-D (cetirizine/pseudoephedrine)	
ANTIMIGRAINE AGENTS, TRIPTANS *Effective 4/2/07*	AMERGE (naratriptan) IMITREX (sumatriptan) MAXALT (rizatriptan) RELPAX (eletriptan)	AXERT (almotriptan) FROVA (frovatriptan) ZOMIG (zolmitriptan)	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Quantity limits apply for this drug class.
ANTIPARKINSON'S AGENTS (Oral) *Effective 10/01/07*	**ANTICHOLINERGICS**		Patients starting therapy on drugs in this class must show a documented allergy to all of the preferred agents, in the corresponding class, before a non-preferred agent will be authorized. Patients currently on a non-preferred agent will be authorized to continue on that agent.
	benztropine KEMADRIN (procyclidine) trihexyphenidyl	COGENTIN (benztropine)	
	COMT INHIBITORS		
		COMTAN (entacapone) TASMAR (tolcapone)	
	DOPAMINE AGONISTS		
	REQUIP (ropinirole)	MIRAPEX (pramipexole)	
	OTHER ANTIPARKINSON'S AGENTS		
	carbidopa/levodopa selegiline STALEVO (levodopa/ carbidopa/entacapone)	AZILECT (rasagiline) ELDEPRYL (selegiline) PARCOPA (levodopa/carbidopa) SINEMET (levodopa/carbidopa) ZELAPAR (selegiline)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
CL - Requires Clinical PA
NR – New drug has not been reviewed by P & T Committee

BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

REVISED 10/02/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

Version 2007.9

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTIPSYCHOTICS, ATYPICAL (Oral) *Effective 10/01/07*	**ORAL**		Treatment naïve patients for this class of drugs will be required to try a preferred agent for two weeks unless one of the exceptions on the PA form is present. Upon discharge, hospitalized patients stabilized on non-preferred agents will receive authorization to continue these drugs for labeled indications and at recommended dosages. Patients currently on Fazaclo will be authorized to continue therapy on that agent.
	clozapine GEODON (ziprasidone) INVEGA (paliperidone) RISPERDAL (risperidone) SEROQUEL (quetiapine)	ABILIFY (aripiprazole) CLOZARIL (clozapine) FAZACLO (clozapine) SEROQUEL XR (quetiapine) NR ZYPREXA (olanzapine)	
	ATYPICAL ANTIPSYCHOTIC/SSRI COMBINATIONS		
		SYMBYAX (olanzapine/fluoxetine)	
ANTIVIRALS (Oral) *Effective 10/01/07*	ANTI-HERPES		All of the appropriate preferred agents must be tried before the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
	acyclovir VALTREX (valacyclovir)	FAMVIR (famciclovir) ZOVIRAX (acyclovir)	
	ANTI INFLUENZA		All of the appropriate preferred agents must be tried before the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
	amantadine	FLUMADINE (rimantadine) rimantadine RELENZA (zanamivir) SYMMETREL (amantadine) TAMIFLU (oseltamivir)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
CL - Requires Clinical PA
NR – New drug has not been reviewed by P & T Committee

BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

REVISED 10/02/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

Version 2007.9

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ATOPIC DERMATITIS *Effective 10/01/07*	ELIDEL (pimecrolimus) PROTOPIC (tacrolimus)		
BETA BLOCKERS (Oral) *Effective 4/2/07*	**BETA BLOCKERS**		If one of the exceptions on the PA form is present or if the physician feels that the patient cannot be stabilized with any of the preferred agents, one of the non-preferred agents will be approved.
	acebutolol atenolol betaxolol bisoprolol INDERAL LA (propranolol) metoprolol nadolol pindolol propranolol sotalol timolol TOPROL XL (metoprolol)	BETAPACE (sotalol) BLOCADREN (timolol) CARTROL (carteolol) CORGARD (nadolol) INNOPRAN XL (propranolol) KERLONE (betaxolol) LEVATOL (penbutolol) LOPRESSOR (metoprolol) SECTRAL (acebutolol) TENORMIN (atenolol) ZEBETA (bisoprolol)	
	BETA- AND ALPHA- BLOCKERS		
	COREG (carvedilol) labetalol	COREG CR (carvedilol)[NR] TRANDATE (labetalol)	
BLADDER RELAXANT PREPARATIONS *Effective 4/2/07*	DITROPAN XL (oxybutynin) ENABLEX (darifenacin) oxybutynin oxybutynin ER OXYTROL (oxybutynin) SANCTURA (trospium) VESICARE (solifenacin)	DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN (oxybutynin)	All of the preferred agents in the class must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
BONE RESORPTION SUPPRESSION AND RELATED AGENTS *Effective 10/01/07*	**BISPHOSPHONATES**		One of the preferred agents must be tried for at least one month before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients currently on a non-preferred agent will be authorized to continue therapy with that agent. Evista will be approved for postmenopausal women with osteoporosis or at high risk for invasive breast cancer.
	FOSAMAX (alendronate) FOSAMAX PLUS D (alendronate/vitamin D)	ACTONEL (risedronate) ACTONEL WITH CALCIUM (risedronate/calcium) BONIVA (ibandronate) DIDRONEL (etidronate)	
	OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS		
	MIACALCIN (calcitonin)	EVISTA (raloxifene)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
[CL] - Requires Clinical PA
[NR] – New drug has not been reviewed by P & T Committee

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		FORTEO (teriparatide) FORTICAL (calcitonin)	
BPH AGENTS *Effective 4/2/07*	**ALPHA BLOCKERS**		One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	doxazosin FLOMAX (tamsulosin) terazosin UROXATRAL (alfuzosin)	CARDURA (doxazosin) CARDURA XL (doxazosin) HYTRIN (terazosin)	
	5-ALPHA-REDUCTASE (5AR) INHIBITORS		
	AVODART (dutasteride)	finasteride PROSCAR (finasteride)	
BRONCHODILATORS, ANTICHOLINERGIC *Effective 10/01/07*	**ANTICHOLINERGIC**		The preferred agents in the class must be tried before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present. For severely compromised patients, albuterol/ipratropium will be approved if the combined volume of albuterol and ipratropium nebules is inhibitory.
	ATROVENT HFA (ipratropium) ipratropium SPIRIVA (tiotropium)	ATROVENT Inhalation Solution (ipratropium)	
	ANTICHOLINERGIC-BETA AGONIST COMBINATIONS		
	COMBIVENT (albuterol/ipratropium)	albuterol/ipratropium DUONEB (albuterol/ipratropium)	
BRONCHODILATORS, BETA AGONIST *Effective 10/01/07*	**INHALERS, SHORT-ACTING**		All of the preferred agents in a group must be tried before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present. Xopenex Inhalation Solution will be approved for 12 months for a diagnosis of asthma or COPD for patients on concurrent asthma controller therapy (either oral or inhaled) with documentation of failure on a trial of albuterol or documented intolerance of albuterol, or for a concurrent diagnosis of heart disease. **No PA is required for ACCUNEB for children up to 5 years of age.
	albuterol CFC MAXAIR (pirbuterol) PROAIR HFA (albuterol) PROVENTIL HFA (albuterol) VENTOLIN HFA (albuterol) XOPENEX HFA (levalbuterol)	ALUPENT (metaproterenol) PROVENTIL (albuterol)	
	INHALERS, LONG-ACTING		
	FORADIL (formoterol)	SEREVENT (salmeterol)	
	INHALATION SOLUTION		
	albuterol	ACCUNEB (albuterol)** BROVANA (arformoterol)[NR] metaproterenol PROVENTIL (albuterol) XOPENEX (levalbuterol)	
	ORAL		

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	albuterol terbutaline	BRETHINE (terbutaline) metaproterenol VOSPIRE ER (albuterol)	
CALCIUM CHANNEL BLOCKERS (Oral) *Effective 4/2/07*	**SHORT-ACTING**		The preferred agents must be tried before a non-preferred agent will be approved.
	diltiazem verapamil	ADALAT (nifedipine) CALAN (verapamil) CARDENE (nicardipine) CARDIZEM (diltiazem) DYNACIRC (isradipine) isradipine nicardipine nifedipine NIMOTOP (nimodipine) PROCARDIA (nifedipine)	
	LONG-ACTING		
	CARDIZEM LA (diltiazem) diltiazem DYNACIRC CR (isradipine) felodipine nifedipine SULAR (nisoldipine) verapamil VERELAN PM (verapamil)	ADALAT CC (nifedipine) amlodipine CALAN SR (verapamil) CARDENE SR (nicardipine) CARDIZEM CD (diltiazem) CARDIZEM SR (diltiazem) COVERA-HS (verapamil) DILACOR XR (diltiazem) ISOPTIN SR (verapamil) NORVASC (amlodipine) PLENDIL (felodipine) PROCARDIA XL (nifedipine) TIAZAC (diltiazem) VERELAN (verapamil)	

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CEPHALOSPORINS AND RELATED ANTIBIOTICS (Oral) *Effective 10/01/07*	**BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS**		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	amoxicillin/clavulanate		
	CEPHALOSPORINS		
	cefaclor cefadroxil cefpodoxime cefprozil cefuroxime cephalexin OMNICEF (cefdinir) SPECTRACEF (cefditoren)	CECLOR (cefaclor) CEDAX (ceftibuten) cefdinir CEFTIN (cefuroxime) CEFZIL (cefprozil) DURICEF (cefadroxil) KEFLEX (cephalexin) PANIXINE (cephalexin) RANICLOR (cefaclor) SUPRAX (cefixime) VANTIN (cefpodoxime)	
CYTOKINE & CAM ANTAGONISTS [CL] *Effective 10/01/07*	ENBREL (etanercept) HUMIRA (adalimumab) KINERET (anakinra) RAPTIVA (efalizumab)		
ERYTHROPOIESIS STIMULATING PROTEINS [CL] *Effective 4/2/07*	ARANESP (darbepoetin) PROCRIT (rHuEPO)	EPOGEN (rHuEPO)	The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
FLUROQUINOLONES, ORAL *Effective 10/01/07*	AVELOX (moxifloxacin) CIPRO (ciprofloxacin) Suspension ciprofloxacin LEVAQUIN (levofloxacin) ciprofloxacin ER	CIPRO (ciprofloxacin) Tablets CIPRO XR (ciprofloxacin) FACTIVE (gemifloxacin) FLOXIN (ofloxacin) ofloxacin NOROXIN (norfloxacin) PROQUIN XR (ciprofloxacin)	One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.

BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

REVISED 10/02/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

Version 2007.9

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
GLUCOCORTICOIDS, INHALED *Effective 10/01/07*	**GLUCOCORTICOIDS** AEROBID (flunisolide) AEROBID-M (flunisolide) ASMANEX (mometasone) AZMACORT (triamcinolone) FLOVENT HFA (fluticasone) QVAR (beclomethasone) **GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS** ADVAIR (fluticasone/salmeterol) ADVAIR HFA (fluticasone/salmeterol)	PULMICORT (budesonide**)** SYMBICORT (budesonide/formoterol)[NR]	All of the preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present. Pulmicort Respules do not require a prior authorization for children through 8 years of age or for individuals unable to use an MDI. When children who have been stabilized on Pulmicort Respules reach age 9, prescriptions for the Pulmicort inhaler will be authorized for them.
GROWTH HORMONE[CL] *Effective 4/2/07*	GENOTROPIN (somatropin) NUTROPIN AQ (somatropin) SAIZEN (somatropin) SEROSTIM (somatropin) TEV-TROPIN (somatropin)	HUMATROPE (somatropin) NORDITROPIN (somatropin) NUTROPIN (somatropin) OMNITROPE (somatropin)[NR] ZORBTIVE (somatropin)	The preferred agents, with the exception of Saizen, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients already on a non-preferred agent will receive authorization to continue therapy on that agent.
HEPATITIS B TREATMENTS *Effective 10/01/07*	EPIVIR HBV (lamivudine) TYZEKA (telbivudine) HEPSERA (adefovir)	BARACLUDE	One of the preferred agents must be tried before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients already on the non-preferred agent will receive authorization to continue therapy on that agent.
HEPATITIS C TREATMENTS[CL] *Effective 4/2/07*	PEGASYS (pegylated interferon) ribavirin	COPEGUS (ribavirin) INFERGEN (consensus interferon) PEG-INTRON (pegylated interferon) REBETOL (ribavirin)	Patients already on a non-preferred interferon will receive authorization to continue therapy on that agent. Patients starting therapy in this class must try preferred agent of a dosage form before a non-preferred agent of that dosage form will be authorized.
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS *Effective 10/01/07*	BYETTA (exenatide) JANUMET (sitagliptin/metformin) JANUVIA (sitagliptin) SYMLIN (amylin)		Byetta and Symlin are both subject to the following step therapy edits: Byetta-Current history of therapy with a sufonlyurea, thiazolindinedione (TZD), and/or metformin No gaps of therapy greater than 30 days in the past 180 days. Symlin-History of insulin utilization in the past 90 days No gaps in therapy of greater than 30 days.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
[CL] - Requires Clinical PA
[NR] – New drug has not been reviewed by P & T Committee

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
HYPOGLYCEMICS, INSULINS *Effective 10/01/07*	HUMALOG (insulin lispro) HUMALOG MIX (insulin lispro/lispro protamine) HUMULIN (insulin) LANTUS (insulin glargine) LEVEMIR (insulin detemir) NOVOLIN (insulin) NOVOLOG (insulin aspart) NOVOLOG MIX (insulin aspart/aspart protamine)	APIDRA (insulin glulisine) EXUBERA (insulin)	To receive authorization for Exubera, patients must meet the following criteria: 1. be 18 years or older; 2. have no history of smoking in the past six months; 3. have no history of chronic lung disease in the past two years or presence of acute lower respiratory lung infection; 4. have a base line spirometry to measure FEV1. For renewal, spirometry to measure FEV1 six months after treatment initiation and then annually from second FEV1 measure; 5. have a diagnosis of Type 1 diabetes (stated or inferred) with concomitant use of a longer acting insulin; OR have a diagnosis of Type 2 diabetes (stated or inferred) and maximization of dosage of at least one available oral agent (sulfonylurea, metformin or thiazolindinediones), unless contraindicated; 6. have a diagnosis of lipodystrophy or needle phobia that prevents self-injection or injection by a caregiver. To receive authorization for Apidra, patients must meet the following criteria: 1. be 18 years or older; 2. be currently on a regimen including a longer-acting or basal insulin. 3. have had a trial of a similar preferred agent, Novolog or Humulin, with documentation that the desired results were not achieved.
HYPOGLYCEMICS, MEGLITINIDES *Effective 4/2/07*	STARLIX (nateglinide)	PRANDIN (repaglinide)	The preferred agent must be tried before a non-preferred agent will be authorized, unless one of the exceptions on the PA form is present.
HYPOGLYCEMICS, TZDS *Effective 4/2/07*	**THIAZOLINEDIONES**		
	ACTOS (pioglitazone) AVANDIA (rosiglitazone)		
	TZD COMBINATIONS		
	ACTOPLUS MET (pioglitazone/metformin) AVANDAMET (rosiglitazone/metformin)		

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	AVANDARYL (rosiglitazone/glimepiride) DUETACT (pioglitazone/glimepiride)		
INTRANASAL RHINITIS AGENTS *Effective 10/01/07*	**ANTICHOLINERGICS**		All of the preferred agents, in corresponding categories, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
		ATROVENT (ipratropium) ipratropium	
	ANTIHISTAMINES		
	ASTELIN (azelastine)		
	CORTICOSTEROIDS		
	FLONASE (fluticasone propionate) NASACORT AQ (triamcinolone) NASONEX (mometasone)	BECONASE AQ (beclomethasone) flunisolide fluticasone propionate NASALIDE (flunisolide) NASAREL (flunisolide) RHINOCORT AQUA (budesonide) VERAMYST (fluticasone furoate)[NR]	
LEUKOTRIENE MODIFIERS *Effective 10/01/07*	ACCOLATE (zafirlukast) SINGULAIR (montelukast)	ZYFLO (zileuton)	
LIPOTROPICS, OTHER (non-statins) *Effective 4/2/07*	**BILE ACID SEQUESTRANTS**		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Zetia, as monotherapy, will only be approved for patients who cannot take statins or other preferred agents. Zetia and Welchol will be approved for add-on therapy only after an insufficient response to the maximum tolerable dose of a statin after 12 weeks of therapy. If patients require the addition of Zetia to Zocor to achieve goal, use of the combination product, Vytorin, will be required. If patients are on other statins and require the addition of Zetia, patients will not be required to switch the statin that they have been using.
	cholestyramine colestipol	COLESTID (colestipol) QUESTRAN (cholestyramine) WELCHOL (colesevalam)	
	CHOLESTEROL ABSORPTION INHIBITORS		
		ZETIA (ezetimibe)	
	FATTY ACIDS		
		OMACOR (omega-3-acid ethyl esters)	
	FIBRIC ACID DERIVATIVES		
	fenofibrate gemfibrozil TRICOR (fenofibrate)	ANTARA (fenofibrate) LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRIGLIDE (fenofibrate)	
	NIACIN		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
[CL] - Requires Clinical PA
[NR] – New drug has not been reviewed by P & T Committee

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	niacin NIASPAN (niacin)	NIACELS (niacin) NIADELAY (niacin) SLO-NIACIN (niacin)	
LIPOTROPICS, STATINS *Effective 4/2/07*	**STATINS**		One of the preferred statins must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ALTOPREV (lovastatin) CRESTOR (rosuvastatin) LESCOL (fluvastatin) LESCOL XL (fluvastatin) LIPITOR (atorvastatin) lovastatin simvastatin	MEVACOR (lovastatin) PRAVACHOL (pravastatin) pravastatin ZOCOR (simvastatin)	
	STATIN COMBINATIONS		
	ADVICOR (lovastatin/niacin) VYTORIN (ezetimibe/simvastatin)	CADUET (atorvastatin/amlodipine)	
MACROLIDES/KETOLIDES (Oral) *Effective 10/01/07*	**MACROLIDES**		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	azithromycin clarithromycin erythromycin	BIAXIN (clarithromycin) BIAXIN XL (clarithromycin) clarithromycin ER E.E.S. (erythromycin ethylsuccinate) E-MYCIN (erythromycin) ERYC (erythromycin) ERYPED (erythromycin ethylsuccinate) ERY-TAB (erythromycin) ERYTHROCIN (erythromycin stearate) erythromycin estolate PCE (erythromycin) ZITHROMAX (azithromycin) ZMAX (azithromycin)	
	KETOLIDES		Requests for telithromycin will be authorized if there is documentation of the use of any antibiotic within the past 28 days.
		KETEK (telithromycin)	
MULTIPLE SCLEROSIS AGENTS[CL] *Effective 4/2/07*	AVONEX (interferon beta-1a) BETASERON (interferon beta-1b) COPAXONE (glatiramer)		

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	REBIF (interferon beta-1a)		
NSAIDS *Effective 10/01/07*	**NONSELECTIVE**		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	diclofenac etodolac fenoprofen flurbiprofen ibuprofen (Rx and OTC) indomethacin ketorolac naproxen (Rx only) oxaprozin piroxicam sulindac	ADVIL (ibuprofen) ANAPROX (naproxen) ANSAID (flurbiprofen) CATAFLAM (diclofenac) CLINORIL (sulindac) DAYPRO (oxaprozin) FELDENE (piroxicam) INDOCIN (indomethacin) ketoprofen LODINE (etodolac) meclofenamate mefenamic acid MOTRIN (ibuprofen) nabumetone NALFON (fenoprofen) NAPRELAN (naproxen) NAPROSYN (naproxen) NUPRIN (ibuprofen) ORUDIS (ketoprofen) PONSTEL (meclofenamate) tolmetin VOLTAREN (diclofenac)	
	NSAID/GI PROTECTANT COMBINATIONS		
		ARTHROTEC (diclofenac/misoprostol) PREVACID NAPRAPAC (naproxen/lansoprazole)	
	COX-II SELECTIVE[CL]		COX-II selective NSAIDs will be approved for patients with a GI Risk Score of ≥13.
		CELEBREX (celecoxib) meloxicam MOBIC (meloxicam)	
OPHTHALMIC FLUOROQUINOLONES	ciprofloxacin ofloxacin	CILOXAN (ciprofloxacin) OCUFLOX (ofloxacin)	All of the preferred agents must be tried before non-preferred agents will be authorized unless one of the exceptions on the PA

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
Effective 10/01/07	VIGAMOX (moxifloxacin)	QUIXIN (levofloxacin) ZYMAR (gatifloxacin)	form is present.
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS *Effective 10/01/07*	ACULAR (ketorolac) ALAWAY (ketotifen) ALREX (loteprednol) cromolyn ELESTAT (epinastine) OPTIVAR (azelastine) PATADAY (olopatadine) PATANOL (olopatadine) ZADITOR OTC (ketotifen)	ALOCRIL (nedocromil) ALAMAST (pemirolast) ALOMIDE (lodoxamide) CROLOM (cromolyn) EMADINE (emedastine) ketotifen OPTICROM (cromolyn)	Two of the preferred agents must be tried before non-preferred agents will be authorized, unless one of the exceptions on the PA form is present.
OPHTHALMICS, GLAUCOMA AGENTS *Effective 10/01/07*	**PARASYMPATHOMIMETICS**		Authorization for a non-preferred agent will only be given if there is an allergy to the preferred agents.
	CARBOPTIC (carbachol) ISOPTO CARBACHOL (carbachol) PHOSPHOLINE IODIDE (echothiophate iodide) pilocarpine	ISOPTO CARPINE (pilocarpine) PILOPINE HS (pilocarpine)	
	SYMPATHOMIMETICS		
	ALPHAGAN P (brimonidine) brimonidine dipivefrin	ALPHAGAN (brimonidine) PROPINE (dipivefrin)	
	BETA BLOCKERS		
	BETIMOL (timolol) BETOPTIC S (betaxolol) betaxolol carteolol ISTALOL (timolol) levobunolol metipranolol timolol	BETAGAN (levobunolol) OPTIPRANOLOL (metipranolol) TIMOPTIC (timolol)	
	CARBONIC ANHYDRASE INHIBITORS		
	AZOPT (brinzolamide) TRUSOPT (dorzolamide)		
	PROSTAGLANDIN ANALOGS		
	LUMIGAN (bimatoprost) TRAVATAN (travoprost) TRAVATAN-Z (travaprost)	XALATAN (latanoprost)	

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

REVISED 10/02/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

Version 2007.9

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	COMBINATION AGENTS		
	COSOPT (dorzolamide/timolol)		
OPHTHALMIC NSAIDS *Effective 10/01/07*	flurbiprofen ACULAR LS (ketorolac) ACULAR PF (ketorolac) XIBROM (bromfenac) NEVANAC (nepafenac)	diclofenac	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
OTIC FLUOROQUINOLONES *Effective 4/2/07*	CIPRODEX (ciprofloxacin/dexamethasone) FLOXIN (ofloxacin)	CIPRO HC (ciprofloxacin/hydrocortisone)	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
PHOSPHATE BINDERS *Effective 4/2/07*	FOSRENOL (lanthanum) PHOSLO (calcium acetate) RENAGEL (sevelamer)		
PLATELET AGGREGATION INHIBITORS *Effective 10/01/07*	AGGRENOX (dipyridamole/ASA) PLAVIX (clopidogrel)	dipyridamole PERSANTINE (dipyridamole) TICLID (ticlopidine) ticlopidine	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
PROTON PUMP INHIBITORS (Oral) *Effective 4/2/07*	NEXIUM (esomeprazole) PREVACID Capsules (lansoprazole)	ACIPHEX (rabeprazole) omeprazole PREVACID Solu-Tabs (lansoprazole) PREVACID Suspension (lansoprazole) PRILOSEC (omeprazole) PROTONIX (pantoprazole) ZEGERID (omeprazole/sodium bicarbonate)	The preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Prior authorization is not required for Prevacid Solu-Tabs for patients ≤8 years of age.
SEDATIVE HYPNOTICS *Effective 4/2/07*	**BENZODIAZEPINES**		The preferred agent must be tried for 14 days before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	temazepam	DALMANE (flurazepam) DORAL (quazepam) estazolam flurazepam HALCION (triazolam) PROSOM (estazolam) RESTORIL (temazepam) triazolam	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
CL - Requires Clinical PA
NR – New drug has not been reviewed by P & T Committee

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	OTHERS		
	zolpidem	AMBIEN (zolpidem) AMBIEN CR (zolpidem) AQUA CHLORAL (chloral hydrate) chloral hydrate LUNESTA (eszopiclone) ROZEREM (ramelteon) SOMNOTE (chloral hydrate) SONATA (zaleplon)	
STIMULANTS AND RELATED AGENTS *Effective 10/01/07*	**AMPHETAMINES**		Except for Strattera, PA is required for adults >18 years. One of the preferred agents in each group (amphetamines and non-amphetamines) must be tried before a non-preferred agent will be authorized. Amphetamines will be authorized for the treatment of depression only after documented failure of multiple antidepressants. Provigil will only be approved for patients >16 years of age with a diagnosis of narcolepsy. Straterra will not be approved for concurrent administration with amphetamines or methyphenidates, exept for 30 days or less for tapering purposes. Only two doses of each strength, or two concurrent doses of any strength, and a maximum of one dose of a 60 mg capsule, will be approved in a 34-day period.
	ADDERALL XR (amphetamine salt combination) amphetamine salt combination dextroamphetamine	ADDERALL (amphetamine salt combination) DESOXYN (methamphetamine) DEXTROSTAT (dextroamphetamine) VYVANSE (lisdexamphetamine) [NR]	
	NON-AMPHETAMINE		
	CONCERTA (methylphenidate) DAYTRANA (methylphenidate) FOCALIN (dexmethylphenidate) FOCALIN XR (dexmethylphenidate) METADATE CD (methylphenidate) methylphenidate methylphenidate ER STRATTERA (atomoxetine)	dexmethylphenidate METADATE ER (methylphenidate) PROVIGIL (modafanil) RITALIN (methylphenidate) RITALIN LA (methylphenidate) RITALIN-SR (methylphenidate)	
ULCERATIVE COLITIS AGENTS *Effective 4/2/07*	**ORAL**		The preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present.
	ASACOL (mesalamine) COLAZAL (balsalazide) DIPENTUM (olsalazine) PENTASA (mesalamine) sulfasalazine	AZULFIDINE (sulfasalazine) LIALDA (mesalamine) [NR]	
	RECTAL		
	CANASA (mesalamine) mesalamine	ROWASA (mesalamine)	